Abstract
Dexrazoxane has been used as an effective cardioprotector against anthracycline cardiotoxicity. This study intended to analyze cardioprotective efficacy and secondary malignancy development, and elucidate risk factors for secondary malignancies in dexrazoxane-treated pediatric patients. Data was collected from 15 hospitals in Korea. Patients who received any anthracyclines, and completed treatment without stem cell transplantation were included. For efficacy evaluation, the incidence of cardiac events and cardiac event-free survival rates were compared. Data about risk factors of secondary malignancies were collected. Data of total 1,453 cases were analyzed; dexrazoxane with every anthracyclines group (D group, 1,035 patients) and no dexrazoxane group (non-D group, 418 patients). Incidence of the reported cardiac events was not statistically different between two groups; however, the cardiac event-free survival rate of patients with more than 400 mg/m2 of anthracyclines was significantly higher in D group (91.2% vs. 80.1%, p=0.04). The 6-year cumulative incidence of secondary malignancy was not different between both groups after considering follow-up duration difference (non-D, 0.52%±0.37%; D, 0.60%±0.28%; p=0.55). The most in...Continue Reading
References
Apr 11, 1992·BMJ : British Medical Journal·M M HawkinsJ M Chessells
Jan 3, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L C KremerP A Voûte
May 27, 2003·Cancer·Sandra M SwainMichael S Ewer
Nov 19, 2003·Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society·Teri Vega-Stromberg
Sep 13, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Nadia HaddyFlorent de Vathaire
Feb 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cameron K TebbiCindy L Schwartz
Mar 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elly V BarryLewis B Silverman
Feb 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven E Lipshultz, M Jacob Adams
Jul 17, 2010·Journal of the National Cancer Institute·Debra L FriedmanJoseph P Neglia
Sep 3, 2010·Journal of Korean Medical Science·Hyoung Soo ChoiJung Yun Choi
Sep 21, 2010·The Lancet Oncology·Steven E LipshultzSteven D Colan
Apr 26, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Lynda M VroomanStephen E Sallan
Nov 30, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Javier G BlancoSmita Bhatia
May 23, 2012·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Carole FarrellAlex Molassiotis
Aug 9, 2012·Future Cardiology·Danielle HarakeSteven E Lipshultz
Sep 6, 2012·Pediatric Blood & Cancer·Dana M WalkerRichard Aplenc
Dec 25, 2013·British Journal of Cancer·D H BrewsterW H Wallace
Mar 29, 2014·Pediatric Blood & Cancer·Alix E SeifRichard Aplenc
Jun 20, 2014·International Journal of Cancer. Journal International Du Cancer·Daniel K ChoiNobuko Hijiya
Jun 3, 2015·Contemporary Oncology Współczesna Onkologia·Dagmara Mozdzanowska, Marek Woźniewski
Jan 6, 2016·British Journal of Haematology·Kaljit S BhullerPaul C Rogers
Citations
Aug 22, 2018·Expert Opinion on Drug Safety·Antonis A ManolisAntonis S Manolis
Jan 29, 2019·Cardio-Oncology·Sarju GanatraSteven E Lipshultz
Mar 11, 2020·Cardio-Oncology·Neha BansalSteven E Lipshultz
Feb 23, 2021·Frontiers in Pediatrics·Varen Zhi Zheng TanChing Kit Chen
Apr 30, 2021·Colombia médica : CM·Adriana Linares BallesterosIván Perdomo Ramírez
Jul 28, 2021·Current Problems in Cardiology·Ashot Avagimyan
Oct 14, 2021·Cancer·Eric J ChowSteven E Lipshultz